The Potential Nexus between Helminths and SARS-CoV-2 Infection: A Literature Review.
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
01
2023
revised:
05
04
2023
accepted:
25
05
2023
medline:
3
7
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
epublish
Résumé
Chronic helminth infections (CHIs) can induce immunological tolerance through the upregulation of regulatory T cells. In coronavirus disease 2019 (COVID-19), abnormal adaptive immune response and exaggerated immune response may cause immune-mediated tissue damage. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and CHIs establish complicated immune interactions due to SARS-CoV-2-induced immunological stimulation and CHIs-induced immunological tolerance. However, COVID-19 severity in patients with CHIs is mild, as immune-suppressive anti-inflammatory cytokines counterbalance the risk of cytokine storm. Since CHIs have immunomodulatory effects, therefore, this narrative review aimed to clarify how CHIs modulate the immunoinflammatory response in SARS-CoV-2 infection. CHIs, through helminth-derived molecules, may suppress SARS-CoV-2 entry and associated hyperinflammation through attenuation of the inflammatory signaling pathway. In addition, CHIs may reduce the COVID-19 severity by reducing the SARS-CoV-2 entry points in the initial phase and immunomodulation in the late phase of the disease by suppressing the release of pro-inflammatory cytokines. In conclusion, CHIs may reduce the severity of SARS-CoV-2 infection by reducing hyperinflammation and exaggerated immune response. Thus, retrospective and prospective studies are recommended in this regard.
Identifiants
pubmed: 37383608
doi: 10.1155/2023/5544819
pmc: PMC10299886
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5544819Informations de copyright
Copyright © 2023 Hayder M. Al-kuraishy et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Pathog Dis. 2013 Nov;69(2):127-41
pubmed: 23929557
J Med Virol. 2021 May;93(5):2735-2739
pubmed: 33506952
Front Pharmacol. 2021 Apr 23;12:642822
pubmed: 33967777
Res Vet Sci. 2018 Apr;117:271-276
pubmed: 29346089
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Life (Basel). 2021 Jul 23;11(8):
pubmed: 34440478
Eur J Immunol. 2010 Jun;40(6):1525-37
pubmed: 20405478
Transplantation. 2014 Jan 27;97(2):127-32
pubmed: 24025322
Sci Rep. 2022 Mar 17;12(1):4586
pubmed: 35302056
PLoS Pathog. 2013;9(8):e1003531
pubmed: 23935505
Travel Med Infect Dis. 2021 Jul-Aug;42:102087
pubmed: 34051352
Front Pharmacol. 2021 Mar 09;12:622554
pubmed: 33767626
PLoS Negl Trop Dis. 2020 Mar 3;14(3):e0008101
pubmed: 32126084
Int Immunopharmacol. 2022 Mar;104:108516
pubmed: 35032828
Am J Trop Med Hyg. 2020 Aug;103(2):564-569
pubmed: 32484156
Microorganisms. 2021 Feb 08;9(2):
pubmed: 33567583
ACS Pharmacol Transl Sci. 2020 Sep 30;3(5):1039-1041
pubmed: 33073203
Front Immunol. 2018 Nov 08;9:2579
pubmed: 30467504
Curr Mol Pharmacol. 2022;15(4):683-692
pubmed: 34477540
Front Immunol. 2020 Oct 20;11:600973
pubmed: 33193456
J Fungi (Basel). 2021 Dec 31;8(1):
pubmed: 35049985
Circ Res. 2018 Mar 30;122(7):970-983
pubmed: 29437833
Front Immunol. 2018 Apr 20;9:763
pubmed: 29731751
J Immunol. 2012 Aug 1;189(3):1459-66
pubmed: 22732589
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
Front Pharmacol. 2020 Aug 07;11:1161
pubmed: 32848769
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Rev Immunol. 2020 Jun;20(6):342
pubmed: 32358579
Biomaterials. 2018 Mar;159:13-24
pubmed: 29309990
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Immunity. 2018 Nov 20;49(5):801-818
pubmed: 30462997
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Trends Parasitol. 2018 May;34(5):388-403
pubmed: 29339033
Ann Hematol. 2022 Sep;101(9):1887-1895
pubmed: 35802164
Sci Afr. 2022 Nov;18:e01407
pubmed: 36310607
Hum Immunol. 2022 Jan;83(1):86-98
pubmed: 34583856
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Curr Pharmacol Rep. 2020;6(4):137-145
pubmed: 32837853
Front Immunol. 2018 Oct 12;9:2349
pubmed: 30369927
Front Mol Biosci. 2020 Jul 03;7:157
pubmed: 32719810
Trop Med Infect Dis. 2022 Jul 30;7(8):
pubmed: 36006249
Blood. 2008 Aug 15;112(4):1290-8
pubmed: 18541719
PLoS One. 2021 May 27;16(5):e0252153
pubmed: 34043673
Inflammopharmacology. 2022 Jun;30(3):811-820
pubmed: 35471628
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
Best Pract Res Clin Gastroenterol. 2008;22(3):511-36
pubmed: 18492569
Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20459-64
pubmed: 21059925
J Allergy Clin Immunol. 2016 Sep;138(3):666-675
pubmed: 27476889
Virol J. 2014 May 06;11:82
pubmed: 24885320
J Immunol. 2000 Jan 1;164(1):183-90
pubmed: 10605010
Inflammopharmacology. 2023 Feb;31(1):1-7
pubmed: 36418600
Naunyn Schmiedebergs Arch Pharmacol. 2021 Oct;394(10):2013-2021
pubmed: 34480616
Science. 2014 Aug 1;345(6196):578-82
pubmed: 25082704
Front Microbiol. 2021 Apr 16;12:614522
pubmed: 33935986
Immun Inflamm Dis. 2022 Mar;10(3):e573
pubmed: 34861106
Science. 2014 Aug 1;345(6196):517-8
pubmed: 25082688
TH Open. 2020 Jun 26;4(2):e138-e144
pubmed: 32607467
Infect Drug Resist. 2021 Oct 27;14:4421-4426
pubmed: 34737582
Mol Biol Rep. 2021 Dec;48(12):8195-8202
pubmed: 34664162
Vaccines (Basel). 2021 Mar 12;9(3):
pubmed: 33809269
Trends Parasitol. 2021 Jan;37(1):11-14
pubmed: 33153921
Life Sci. 2020 Dec 1;262:118552
pubmed: 33035583
Front Pharmacol. 2020 Aug 28;11:1333
pubmed: 32982743
Semin Immunopathol. 2012 Nov;34(6):889-901
pubmed: 23129304
J Microbiol Immunol Infect. 2021 Feb;54(1):61-68
pubmed: 33468435
BMC Med. 2022 Jun 28;20(1):241
pubmed: 35764965
PLoS Negl Trop Dis. 2021 May 24;15(5):e0009402
pubmed: 34029332
Cell Rep. 2019 Nov 19;29(8):2243-2256.e4
pubmed: 31747598
Evol Med Public Health. 2021 Feb 12;9(1):120-130
pubmed: 33732461
Mol Immunol. 2021 Sep;137:124-133
pubmed: 34246032
Heliyon. 2019 Jan 31;5(1):e01161
pubmed: 30775568
Inflammopharmacology. 2022 Dec;30(6):2017-2026
pubmed: 36044102
Inflammopharmacology. 2022 Dec;30(6):2411-2415
pubmed: 36180664
Clin Microbiol Rev. 2004 Oct;17(4):1012-30, table of contents
pubmed: 15489359
Nat Med. 2012 Jan 15;18(2):260-6
pubmed: 22245779
Int J Cancer. 2019 Dec 1;145(11):3126-3139
pubmed: 31407335
FASEB J. 2017 Jan;31(1):85-95
pubmed: 27682204
Front Cardiovasc Med. 2021 May 20;8:644095
pubmed: 34124187
Front Microbiol. 2013 Oct 01;4:296
pubmed: 24101918
Curr Med Chem. 2023;30(34):3832-3845
pubmed: 36043749
Curr Allergy Asthma Rep. 2010 Jan;10(1):3-12
pubmed: 20425508
Int J Lab Hematol. 2021 Jul;43 Suppl 1:137-141
pubmed: 33289964
Pathogens. 2022 Mar 02;11(3):
pubmed: 35335634
Nat Commun. 2017 Jan 27;8:14208
pubmed: 28128208
Evol Med Public Health. 2020 Oct 20;2020(1):234-248
pubmed: 33235797
Front Cell Neurosci. 2015 Nov 25;9:452
pubmed: 26635531
Front Immunol. 2020 Oct 08;11:574910
pubmed: 33117371
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Parasite Immunol. 2006 Nov;28(11):613-23
pubmed: 17042933
Pulm Pharmacol Ther. 2021 Apr;67:102008
pubmed: 33727066
Future Sci OA. 2022 Apr 14;8(5):FSO797
pubmed: 35662743
Parasite Immunol. 2006 Oct;28(10):483-96
pubmed: 16965284
PLoS Negl Trop Dis. 2019 Dec 9;13(12):e0007908
pubmed: 31815932
Eur Arch Otorhinolaryngol. 2021 Jul;278(7):2637-2640
pubmed: 33025046
PLoS Negl Trop Dis. 2020 Aug 17;14(8):e0008628
pubmed: 32804930
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221103151
pubmed: 35590466
Future Microbiol. 2021 Apr;16:371-374
pubmed: 33847161
J Med Virol. 2020 Oct;92(10):2105-2113
pubmed: 32383269
EClinicalMedicine. 2020 May 03;23:100375
pubmed: 32368728
Signal Transduct Target Ther. 2020 Jul 25;5(1):128
pubmed: 32712629
Circ Res. 2023 Feb 3;132(3):290-305
pubmed: 36636919
PLoS Negl Trop Dis. 2019 Mar 21;13(3):e0007265
pubmed: 30897083
Infect Immun. 2018 Oct 25;86(11):
pubmed: 30104215
Mucosal Immunol. 2020 Mar;13(2):357-370
pubmed: 31776431
Travel Med Infect Dis. 2021 Mar-Apr;40:101981
pubmed: 33535106
Hum Vaccin Immunother. 2020 Oct 2;16(10):2363-2365
pubmed: 32841579
Inflammopharmacology. 2022 Dec;30(6):1993-2001
pubmed: 36114383
Front Immunol. 2018 Apr 04;9:664
pubmed: 29670630
Allergy. 2020 Mar;75(3):524-534
pubmed: 31187881
Biochem Biophys Res Commun. 2021 Jan 29;538:92-96
pubmed: 33168188
Pan Afr Med J. 2020 May 15;35(Suppl 2):36
pubmed: 33623561
Sci Rep. 2019 Feb 19;9(1):2275
pubmed: 30783117
Mol Cell Biochem. 2021 Nov;476(11):4161-4166
pubmed: 34319496
Exp Gerontol. 2020 May;133:110852
pubmed: 32007545
Int J Parasitol. 2017 Jan;47(1):1-10
pubmed: 28003150
Front Immunol. 2020 Jun 23;11:1518
pubmed: 32655582
J Immunol. 2012 May 1;188(9):4188-99
pubmed: 22461700
EClinicalMedicine. 2021 Sep;39:101054
pubmed: 34368662
Integr Comp Biol. 2019 Nov 1;59(5):1190-1202
pubmed: 31368489
Int J Clin Pharm. 2022 Jun;44(3):832-833
pubmed: 35449348
J Allergy Clin Immunol. 2020 Jul;146(1):203-206.e3
pubmed: 32333915
Emerg Infect Dis. 2022 Jul;28(7):1531-1533
pubmed: 35731220
Syst Rev. 2021 Jul 10;10(1):203
pubmed: 34246316
J Microsc Ultrastruct. 2020 Dec 10;8(4):141-145
pubmed: 33623736
Front Pharmacol. 2022 Apr 26;13:884228
pubmed: 35559257
mBio. 2020 Aug 7;11(4):
pubmed: 32769090
Nat Rev Immunol. 2011 Jun;11(6):375-88
pubmed: 21610741
Curr Top Microbiol Immunol. 2014;385:327-56
pubmed: 25027822
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432